CN1502340A - Process for prepaing ginkgo leaf dispersion tablet - Google Patents
Process for prepaing ginkgo leaf dispersion tablet Download PDFInfo
- Publication number
- CN1502340A CN1502340A CNA021341265A CN02134126A CN1502340A CN 1502340 A CN1502340 A CN 1502340A CN A021341265 A CNA021341265 A CN A021341265A CN 02134126 A CN02134126 A CN 02134126A CN 1502340 A CN1502340 A CN 1502340A
- Authority
- CN
- China
- Prior art keywords
- less
- dispersible tablet
- adjuvant
- folium ginkgo
- ginkgo leaf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a preparation method of ginkgo leaf dispersing tablet, and it is characterized by that it uses the ginkgo leaf as raw material, and adopts an extraction process to obtain the ginkgo leaf extract in which the bilobalide and flavone can be used as main effective component, then adds the auxiliary material as disintegrant whose degree of swelling is greater than 5 ml/g, and the added ratio of the disintegrant is not less than 5% of total tablet weight and is not greater than 30%, and then adds other filling auxiliary material and flow aid so as to obtain the invented dispersing tablet for curing coronary heart disease, stable angina cordis and cerebral infarction. Its disintegration time is less than 180 sec.
Description
The technical field pharmaceutical technology
The background technology Folium Ginkgo is the conventional Chinese medicine material, generally at first is processed into the extract based on bilobalide and flavones ingredient, further is processed into various preparations again.By prescription or be used for the treatment of the thoracic obstruction that obstruction of collaterals by blood stasis causes, pained, apoplexy, hemiplegia, stiff tongue language separately and hold high up; Coronary heart disease stable angina pectoris, cerebral infarction see above-mentioned symptom person.
A kind of very practical novel form that dispersible tablet is that the eighties, the America and Europe began one's study belongs to quick-effective preparation, have rapid-action, the bioavailability height; Promptly can be used as tablet and swallow, also take in the water soluble, be suitable for dissimilar patients; Dissolution velocity can be compared with freeze-dried instant sheet or effervescent tablet in water, and does not need special special equipment and complicated preparation technology, does not also have the such soda acid incompatibility of effervescent tablet, can use common characteristics such as tablet device fabrication.Its disintegrate in 180 seconds in 19-21 ℃ of water; Slice, thin piece is placed on and is stirred to the homogeneous dispersion that disperses the back to form fully in the 100ML water.Dispersible tablet adds after the aqueous dispersion oral, also dispersible tablet can be contained with mouthful in suck clothes or swallow.For fat-soluble medicine, dispersible tablet is fit closely dosage form.
Based on the Folium Ginkgo extract of bilobalide and flavones ingredient, the general extraction with organic solvents such as ethanol generally is processed into conventional tablet or capsule now and used, and bioavailability is low; Use the problem solved bioavailability though be processed into injection, use inconvenience, clinical needs are a kind of efficiently, dosage form easily, the problem that the present invention that Here it is solves.
Summary of the invention is crude drug with the Folium Ginkgo, at first processing is extracted and to be able to bilobalide and flavones ingredient is main extract, further adding swellbility again is disintegrating agent greater than the adjuvant of 5ml/g, as carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (LS-HPC), crospolyvinylpyrrolidone (PVPP), cross-linking sodium carboxymethyl cellulose (CCMC-Na) etc., additional proportion be not less than total sheet heavy 5%, and be not more than 30%, and further add other and fill adjuvant (as: starch, microcrystalline Cellulose etc.) and fluidizer etc., make disintegration time less than 180 seconds, and " two appendix of Chinese pharmacopoeia are about the relevant requirements of " dispersible tablet " to meet version in 2000.
The specific embodiment is got Folium Ginkgo and is extracted with Diluted Alcohol processing and make bilobalide-containing and be no less than 6%, the total flavonoid composition is no less than 24% Folium Ginkgo extract, the adding swellbility is a disintegrating agent greater than the adjuvant of 5ml/g, as carboxymethyl starch sodium (CMS-Na), low-substituted hydroxypropyl cellulose (LS-HPC), crospolyvinylpyrrolidone (PVPP), cross-linking sodium carboxymethyl cellulose (CCMC-Na) etc., additional proportion be not less than total sheet heavy 5%, and be not more than 30%, and further add other and fill adjuvant (as: starch, microcrystalline Cellulose etc.) and fluidizer etc., make disintegration time less than 180 seconds, and " two appendix of Chinese pharmacopoeia are about the relevant requirements of " dispersible tablet " to meet version in 2000.Being used for the treatment of the thoracic obstruction that obstruction of collaterals by blood stasis causes, pained, apoplexy, hemiplegia, stiff tongue language holds high up; Coronary heart disease stable angina pectoris, cerebral infarction see above-mentioned symptom person.
Claims (1)
- With the total technical characterictic of prior art be Folium Ginkgo extract to be used for the treatment of disease be known technology, and existing several formulations existence except that dispersible tablet; The preparation method of dispersible tablet is a known technology.Its technical characterictic is to be crude drug with the Folium Ginkgo, at first processing is extracted and to be able to bilobalide and flavones ingredient is main extract, further adding swellbility again is disintegrating agent greater than the adjuvant of 5ml/g, as carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose etc., additional proportion be not less than total sheet heavy 5%, and be not more than 30%, and further add other and fill adjuvant (as: starch, microcrystalline Cellulose etc.) and fluidizer etc., make disintegration time less than 180 seconds, and " two appendix of Chinese pharmacopoeia are about the relevant requirements of " dispersible tablet " to meet version in 2000.With the Folium Ginkgo is raw material, the processing extraction makes bilobalide-containing and is no less than 6%, the total flavonoid composition is no less than 24% Folium Ginkgo extract, add disintegrating agent (as: carboxymethyl starch sodium, low-substituted hydroxypropyl cellulose, crospolyvinylpyrrolidone, cross-linking sodium carboxymethyl cellulose etc.), independent or the mixing adding of above disintegrating agent, but toatl proportion be not less than total sheet heavy 5%, also be not more than 30%, and can add other filling adjuvant (as: starch, microcrystalline Cellulose etc.) and preparation tablets such as fluidizer adjuvant commonly used, make disintegration time less than 180 seconds, and " two appendix of Chinese pharmacopoeia are about the dispersible tablet of other relevant requirements of " dispersible tablet " to meet version in 2000.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021341265A CN1502340A (en) | 2002-11-21 | 2002-11-21 | Process for prepaing ginkgo leaf dispersion tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNA021341265A CN1502340A (en) | 2002-11-21 | 2002-11-21 | Process for prepaing ginkgo leaf dispersion tablet |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1502340A true CN1502340A (en) | 2004-06-09 |
Family
ID=34231386
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA021341265A Pending CN1502340A (en) | 2002-11-21 | 2002-11-21 | Process for prepaing ginkgo leaf dispersion tablet |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1502340A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063267A1 (en) * | 2003-12-31 | 2005-07-14 | Beijing Kexin Bicheng Medical Technology Development Co., Ltd. | The oral disintegratable tablet of ginkgo leaves |
| CN1323667C (en) * | 2004-08-04 | 2007-07-04 | 云南白药集团股份有限公司 | Notoginseng dispersible tablet and its preparing process |
-
2002
- 2002-11-21 CN CNA021341265A patent/CN1502340A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005063267A1 (en) * | 2003-12-31 | 2005-07-14 | Beijing Kexin Bicheng Medical Technology Development Co., Ltd. | The oral disintegratable tablet of ginkgo leaves |
| CN1323667C (en) * | 2004-08-04 | 2007-07-04 | 云南白药集团股份有限公司 | Notoginseng dispersible tablet and its preparing process |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2318601A (en) | Withania somnifera composition | |
| JP2818220B2 (en) | Composition containing water-containing organic solvent extract for food, composition containing water-containing organic solvent extract for medicine, and methods for producing them | |
| CN101732668B (en) | Preparation method of Chinese medicinal composition for treating urinary system infection | |
| CN104983844A (en) | Edible composition formula with mucous-membrane restoring function and preparation process of preparation thereof | |
| CN102085344B (en) | Aplotaxis carminative sustained-release preparation and preparation method thereof | |
| CN103239507A (en) | Medicinal composition capable of being rapidly disintegrated and dissolved in oral cavity and preparation method thereof | |
| CN101108872A (en) | Plants natural base extractive and formulated product and use thereof | |
| CN108813465A (en) | A kind of fig function chewable tablets and preparation method thereof | |
| CN102824353B (en) | A kind of helicide oral formulations and its preparation method and application | |
| CN104000797A (en) | Pharmaceutic preparation including mangiferin glycoside and preparation method thereof | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN112294883B (en) | Stomach-strengthening tablet medicinal preparation and preparation method thereof | |
| US20210032374A1 (en) | Isolated saposhnikovia divaricata polysaccharide and use thereof | |
| CN1502340A (en) | Process for prepaing ginkgo leaf dispersion tablet | |
| CN1799582A (en) | Blood sugar- and blood pressure-lowering medicine | |
| CN101108224B (en) | Plants natural base extractive and formulated product and use thereof | |
| CN101292977B (en) | Pharmaceutical combination with stable strontium ranelate and its preparations | |
| CN107582866B (en) | Application method of dendrobium officinale and amlodipine in preparation of medicine for treating hypertension | |
| CN102525972A (en) | Calcium-ion antagonist orally disintegrating tablet and preparation method thereof | |
| KR20100022711A (en) | Solid dispersion comprising an extract of scutellariae radix, the oral formulation comprising the same and the preparation method thereof | |
| CN101040905B (en) | Medicine made by selfheal for reducing blood sugar | |
| Kandekar et al. | Fenugreek: Novel delivery technologies and versatile formulation excipients | |
| CN1321645C (en) | Oral effervesce tablets for treating cardiovascular and cerebrovascular diseases, and prepn. method therefor | |
| CN102772455A (en) | Seabuckthorn flavone dispersible tablets | |
| WO2017219453A1 (en) | Valsartan dispersible tablet and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |